We are seeing patients in-person and through Video Visits. Learn more about how we’re keeping you safe and please review our updated visitor policy. Please also consider supporting Weill Cornell Medicine’s efforts to support our front-line workers.

You are here

Use of Adenosine to Determine the Electrophysiological Mechanism of Premature Ventricular Contractions

IRB Protocol #: 1609017561

Overview: The purpose of this study is to learn more about the underlying mechanism of the heart rhythm disorder, or “arrhythmia,” known as premature ventricular contractions (PVCs), by testing whether PVCs can be terminated by a cardiac medication known as adenosine. Previous studies have given us some reasons to believe that the answer is yes, but it is not known for sure. The findings of this study may help us understand how this cardiac condition comes about, and may ultimately lead to new treatments for it (and possibly other arrhythmias).

This trial is not funded.

Eligible patients must:

•          Be older than 18

•          Have frequent monomorphic PVCs

•          Be undergoing a catheter ablation

Patients cannot participate if:

•          Diagnosed with severe aortic stenosis

•          Diagnosed with structural heart disease

•          Currently being treated with antiarrhythmic drugs

•          Diagnosed with asthma


Dr. James Ip
Principle Investigator
Email: jei9008@med.cornell.edu
Phone: (212) 746-2158 

Rosa Chu
Research Coordinator
Email: roc2025@med.cornell.edu
Phone: (212) 746-4857

Make an Appointment

(646) 962-5558

Weill Cornell Medicine
Division of Cardiology

520 East 70th Street
Starr 443
New York, NY 10021

1305 York Avenue, 8th Floor
New York, NY 10021